Northland Securities started coverage on shares of BioLife Solutions (NASDAQ:BLFS) in a research note issued on Monday. The brokerage set an “outperform” rating on the medical equipment provider’s stock.
Separately, Maxim Group set a $8.00 price target on shares of BioLife Solutions and gave the stock a “buy” rating in a research note on Friday, March 9th.
BioLife Solutions (BLFS) opened at $5.26 on Monday. The stock has a market cap of $71.70, a PE ratio of -25.05 and a beta of 0.38. BioLife Solutions has a one year low of $1.95 and a one year high of $7.53.
In related news, CEO Michael Rice sold 12,540 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $5.57, for a total value of $69,847.80. Following the transaction, the chief executive officer now owns 152,057 shares in the company, valued at approximately $846,957.49. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 36.80% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Essex Investment Management Co. LLC lifted its stake in BioLife Solutions by 199.8% during the 4th quarter. Essex Investment Management Co. LLC now owns 254,096 shares of the medical equipment provider’s stock valued at $1,525,000 after acquiring an additional 169,341 shares during the period. Granite Investment Partners LLC bought a new position in BioLife Solutions during the 3rd quarter valued at about $1,205,000. Millennium Management LLC lifted its stake in BioLife Solutions by 901.6% during the 4th quarter. Millennium Management LLC now owns 182,550 shares of the medical equipment provider’s stock valued at $1,095,000 after acquiring an additional 164,324 shares during the period. EAM Investors LLC bought a new position in BioLife Solutions during the 3rd quarter valued at about $555,000. Finally, Wells Fargo & Company MN bought a new position in BioLife Solutions during the 4th quarter valued at about $111,000. Institutional investors and hedge funds own 12.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “BioLife Solutions (BLFS) Now Covered by Analysts at Northland Securities” was published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.themarketsdaily.com/2018/03/14/biolife-solutions-blfs-now-covered-by-analysts-at-northland-securities.html.
About BioLife Solutions
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.